Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

Kidney dosimetry during 177Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

“…The clinical value of PRRT in patients with disseminated neuroendocrine tumors has been reported in several publications [1,2,4,9]. However, many issues remain to be solved in order to improve and personalize the therapy [25]. There is a general agreement in the literature on the importance of individualized therapy using dosimetry as a tool to achieve an individual risk-assessment for sensitive organs [26].…”

Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours

“…A range of publications during recent years has reported on the clinical value of radionuclide therapy directed towards somatostatin receptors for therapy of patients with neuroendocrine tumours [ 3 , 4 , 6 , 13 ]. Still, many issues remain to be solved in order to improve and personalize the therapy [ 26 ]. In the literature, a general agreement on the importance of individualized therapy is noted, where dosimetry is one tool to achieve an individual risk-assessment for sensitive organs [ 27 ].…”

The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis

“…Although there was no difference in overall survival (OS) between patient groups undergoing PRRT with 90 Y and 177 Lu [6], the advantage of using 90 Y for larger tumours and 177 Lu for smaller tumours was suggested, based on animal models [7]. PRRT is generally well tolerated with a major concern for nephrotoxicity and haematotoxicity [8]. However, the risk of nephrotoxicity or haematotoxicity is less with 177 Lu-labelled PRRT [9].…”